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Immunotherapy with subcutaneous 
immunogenic autologous 
tumor lysate increases murine 
glioblastoma survival
Jochen Belmans1, Matthias Van Woensel2,3, Brecht Creyns4, Joost Dejaegher2, Dominique M. 
Bullens1,5 & Stefaan W. Van Gool1,6
Immunotherapeutic strategies for glioblastoma, the most frequent malignant primary brain tumor, 
aim to improve its disastrous consequences. On top of the standard treatment, one strategy uses T 
cell activation by autologous dendritic cells (DC) ex vivo loaded with tumor lysate to attack remaining 
cancer cells. Wondering whether ‘targeting’ in vivo DCs could replace these ex vivo ones, immunogenic 
autologous tumor lysate was used to treat glioma-inoculated mice in the absence of ex vivo loaded 
DCs. Potential immune mechanisms were studied in two orthotopic, immunocompetent murine glioma 
models. Pre-tumoral subcutaneous lysate treatment resulted in a survival benefit comparable to 
subcutaneous DC therapy. Focussing on the immune response, glioma T cell infiltration was observed 
in parallel with decreased amounts of regulatory T cells. Moreover, these results were accompanied 
by the presence of strong tumor-specific immunological memory, shown by complete survival of 
a second glioblastoma tumor, inoculated 100 days after the first one. Finally, in combination with 
temozolomide, survival of established glioma in mice could be increased. Our results show the potential 
of immunogenic autologous tumor lysate used to treat murine glioblastoma, which will be worthwhile 
to study in clinical trials as it has potential as a cost-efficient adjuvant treatment strategy for gliomas.
Amongst brain tumors, glioblastoma multiforme (GBM) can be considered the greatest nemesis, being the most 
aggressive and common primary brain tumor1. The disease is part of the high grade gliomas (HGG) and is clas-
sified as a grade IV malignancy according to the World Health Organisation2,3. With a limited incidence of 4 in 
100.000 people, GBM still has a very high socioeconomic impact4,5. Even though patients are intensively treated, 
the prognosis remains dismal with a median survival of only 14.6 months6,7. Therefore a lot of effort is put in 
adjuvant therapies such as cancer immunotherapy8,9.
For GBM, especially vaccination strategies using dendritic cells (DC) have been tested, frequently with the 
use of whole tumor lysate10. DC immunotherapy consists of patient-derived DCs differentiated ex vivo often 
from harvested monocytes and loaded with autologous tumor lysate. Recently a meta-analysis shows that DC 
immunotherapy has a limited long-term effect in human GBM11. Within our group preclinical optimisation of 
DC immunotherapy in the murine GL261 glioma model has been studied12,13. Therefore, different formulations of 
tumor lysate were created and tested in vitro and in vivo. Both cited studies conclude that the immunogenicity of 
the lysate loaded to the DCs is important. Changing the protocol to create lysate will change its immunogenicity.
The effect of tumor lysate without the addition of DCs to treat cancer has been reported for different cancer 
types e.g. melanoma, prostate cancer, glioma, …14–16. Studies describing this effect often make use of adjuvants 
added to the lysate in different forms e.g. cytokines such as GM-CSF and IL1217; (gene transduced) allogenic 
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cells15,18–20, heat shock proteins (HSP65 and HSP96)16,21 or CpG oligodeoxynucleotide22,23. Injection of autologous 
tumor lysate in the absence of adjuvants was performed in only two studies as a cancer treatment24–26. However 
some remarks need to be taken into account. In a preclinical glioma model by Jouanneau et al., an impressive 
improvement in long-term survival was observed in glioma-bearing mice treated with tumor lysate24. Tumor 
lysate in that study was used as a boost injection after initial priming with lysate loaded DCs. These boost injec-
tions were superior when compared to a second lysate loaded DC vaccination in their model. In a human clinical 
trial, to treat renal cell carcinoma, autologous lysate treatment was used as an adjuvant therapy after nephrec-
tomy25,26. Before lysate preparation, isolated tumor cells were grown in medium supplemented with interferon-γ 
(IFN-γ) and tocopherol acetate to increase their immunogenicity. Autologous tumor cell vaccination in compar-
ison to no additional treatment resulted in an improved survival in T3 staged patients. These studies show that 
injecting lysate has potential as a treatment modality.
Here we investigated the potential effect and immune mechanisms of immunogenic autologous tumor lysate, 
in the absence of DCs and adjuvants, to treat malignant gliomas in an orthotopic mouse model. We hypothesize 
that lysate once injected subcutaneously will be taken up by skin residing DCs in vivo and this way is able to create 
an immune response against tumor cells. Our findings suggest autologous lysate treatment is able to create an 
immune response with long-lasting memory in a murine glioma model. As the injection of tumor lysate instead 
of ex vivo loaded DCs is more cost efficient and reduces the number of procedures by personnel, the described 
study is justified and might have important implications in how to “vaccinate” GBM patients in combination with 
standard therapy.
Results
Uptake of lysate and presentation of lysate fragments by DCs in vitro. Before in vivo testing, we 
investigated uptake of tumor lysate fragments by DCs in vitro as previously published by De Vleeschouwer et 
al. in a human setting27. For this, lysate was labelled with FITC and added in vitro to iDCs. Both fluorescence 
microscopy and flow cytometry indicated the uptake of lysate fragments by visualisation of FITC positive DCs 
(data not shown). To discriminate between uptake of lysate versus surface adhesion to DC membranes, confocal 
microscopy was performed. We could demonstrate that lysate-FITC complexes were internalized after 90 minutes 
of incubation (Fig. 1A and Supplementary movie). Confirmation of this observation was obtained by trypan blue 
quenching of the surface FITC signal (Supplementary Fig. 1, upper panel). Following FITC surface quenching the 
positive intracellular signal was still present, indicating uptake by DCs. Moreover, to examine whether the uptake 
is an active physiologic process, loading of DCs with lysate-FITC was performed at 37 °C or at 4 °C, a temperature 
at which all cell metabolism is shut down27. Uptake of lysate fragments was only observed in the 37 °C condition, 
indicating an active uptake mechanism of these fragments by DCs (Supplementary Fig. 1, lower panel).
To complete the in vitro study we aimed to demonstrate the processing of lysate, which is necessary to create 
an immune response against tumor cells. Using confocal microscopy, colocalization of FITC-lysate fragments 
with MHC-I molecules was found (Fig. 1B). Moreover, maturation of DCs was observed when lysate was pre-
sented to the DCs (Fig. 1C and Supplementary Fig. 2). Together these results indicate that (cross-)presentation of 
lysate fragments in MHC-I context is possible when lysate is loaded to DCs.
Pre-tumor lysate treatment improves survival in a murine glioma model. Following the in vitro 
confirmation of lysate uptake and processing by DCs, we wanted to study whether autologous lysate is clinically 
active. In an intracranial GL261 glioma model of fully immunocompetent mice we compared tumor growth in 
the absence or presence of treatment. The murine GL261 glioma model is the standard model to test immuno-
therapy in GBM and has already been used in our group for over a decade28–30. Due to the aggressive nature of 
GL261 glioma, prophylactic immunisation was performed 14 and 7 days before tumor inoculation (Fig. 2). In line 
with previous published studies, we started testing the clinical activity of lysate after i.p. injection31. In comparison 
to mock treated mice, animals in the test-condition showed an increased median survival with 25% LT-surviving 
mice (Fig. 2A). With the relative amount of DCs being greater in the skin as compared to the peritoneum32 and 
our hypothesis stating these cells as the most important cells to create an immune response following lysate 
injection, the s.c. injection route was studied next. As observed after i.p. injections, s.c. pre-tumor lysate treat-
ment showed a similar positive effect on the survival of mice in comparison to mock injected mice (Fig. 2B). By 
including a group of mice treated with s.c. DC therapy, no differences could be observed in comparison to lysate 
treatment. We then studied whether we could confirm these results in the CT2A cell line, predominantly used for 
studying glioma stem cells, but with several GBM features such as a high infiltrative nature and high mitotic index 
and cell density30,33. Retaining the pre-tumor treatment schedule of the GL261 model, the CT2A model resulted 
in 80% of the lysate-treated mice surviving tumor inoculation over 120 days (Fig. 2C). In comparison, the s.c. DC 
therapy in this CT2A model also improved survival, although less effective as the lysate treatment. These results 
clearly indicate the potential of autologous lysate therapy in glioma mouse models.
In search for a more universal immunotherapy treatment, some researchers have suggested to use the lysate of 
multiple HLA-matching reference tumor cell lines18. Therefore we wondered whether a non-autologous treatment 
would be able to treat mice glioma. This can be elicited by pre-treatment of mice with lysate of one cell line and 
testing if this could help mice intracranially injected with tumor cells of the other cell line. GL261 and CT2A cells 
are both syngeneic cell lines for C57BL/6 mice but originate from different cells30 and therefore could be used 
to test the effect of syngeneic treatment with non-autologous tumor lysate (Supplementary Fig. 3). Syngeneic 
pre-tumor treatment with CT2A lysate resulted in increased survival of GL261 cell inoculated mice, with three 
out of four mice surviving tumor over 150 days. Syngeneic pre-tumor treatment with GL261 lysate however 
did not show significant improvement for CT2A glioma-bearing mice, although one mouse did survive tumor 
inoculation over 100 days. Showing one-way cross-reactivity, these results suggest the importance of (tumor) 
specificity in GBM.
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Early after tumor inoculation, lysate treatment induced a T cell influx combined with dimin-
ished immune suppression in the brain. To investigate the immune response induced by autologous 
lysate treatment, brain infiltrating immune cells, and more specifically the T cell populations, were studied. 
Because of its invasive character, more resembling GBM, the CT2A model was used for this experiment30,33. 
Pre-treated mice were tumor inoculated and sacrificed 7, 14, 21 or 28 days later to isolate the brain immune cells. 
Flow cytometry was used to study the proportions of different T cell populations of lysate treated mice in compar-
ison to mock treated animals. The gating strategy used for the population analysis is depicted in Supplementary 
Figs 4 and 5. At the earliest time point, day 7, influx of total T lymphocytes (CD3+) was detected. As shown in 
Fig. 3, this resulted in an increased proportion of CD4+ but not CD8+ T cells. Although the relative amount of 
CD4+ T cells was increased, the proportion of CD4+Foxp3+ regulatory T cells (Treg) was decreased, pointing 
to decreased immune suppression. Together these results indicate a shift from immune suppression to immune 
activation 7 days after tumor inoculation due to lysate pre-treatment. At day 21, but not day 14 nor day 28, we also 
observed an increased proportion of total T lymphocytes, with a lower frequency of Tregs infiltrating the tumor 
environment (Fig. 3).
Figure 1. Uptake and cross-presentation of lysate fragments by dendritic cells in vitro. In vitro differentiated 
DCs were incubated with FITC labelled lysate for 90 minutes, afterwards washed and stained in the uptake 
experiments (A) or matured with LPS in the cross-presentation experiments (B). (A) Z-stack images, obtained 
with confocal microscopy, were used to visualize DCs and prove real uptake of lysate. Picture (A) represents 
one slice of the confocal z-stack with DAPI nucleus staining (blue) and FITC signal (green). (B) Maturation 
of DCs was ended after 24 hours by washing cells, fixation and staining. (B) Confocal microscopy showed 
colocalization (yellow signal) of fragments of lysate (FITC, green signal) and MHC class I molecules (PE, red 
signal). The box at the bottom is a magnification of the marked cells. (C) Flow cytometry was used to study the 
expression of maturation markers on lysate loaded DCs. In vitro differentiated DCs were incubated with lysate 
for 90 minutes, washed and after 24 hours incubation stained. Representative graphs for DC maturation markers 
CD40 and CD86 are shown with expression on immature DCs in blue and marker expression by mature DCs in 
red. Images were visualized with a 400x magnification and all pictures and graphs are representative of at least 
three independent experiments.
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From a longitudinal point of view (Fig. 3), an increased proportion of CD3+ T cells was observed which cor-
related with increased relative amount of CD8+ T cells. Importantly, this increase of CD8+ T cells was accompa-
nied by an influx of IFNγ-producing CD8+ T cells over time both for the lysate treated and PBS treated animals. 
Kinetic analysis of CD4+ T cells showed a decrease in frequency starting between day 7 and 14, indicating an 
important role mainly at the first time point. Overall it was concluded that the immune response is driven both 
by CD4+ and CD8+ T cells.
Peripheral immune response was studied by investigating T cell populations in spleen and draining lymph 
nodes of pre-treated mice at day 21 after tumor inoculation. For the draining lymph nodes, cells from ingui-
nal and axillary lymph nodes were pooled and the same flow cytometric stainings and gating strategy as for 
the brain infiltrating immune cell study were used. Among the splenocytes, a decreased proportion in Treg 
cells was detected for autologous lysate treated mice as compared to PBS treated animals (data not shown). On 
the other hand, no difference was detected for the IFN-γ producing T cells. Moreover, neither cell population 
showed any difference in the lymph nodes. It can be concluded that these data suggest the presence of an overall 
immune-suppression by autologous lysate treatment.
Pre-tumor lysate treatment induces a long-lasting immunological memory. Another charac-
teristic of the adaptive immunity is the presence of memory cells, which can fasten an immune response in the 
case of second exposure or relapsed disease. In search for an indication of immunologic memory, mice were 
pre-treated with lysate more than 100 days prior to tumor inoculation. The experiment was performed in the 
GL261 and CT2A model and resulted in strong protection from tumor growth (Fig. 4). These results were verified 
by rechallenge of LT survivors of the experiments described above. The animals were intracranially inoculated 
with the same amount of autologous tumor cells at the contralateral side of the brain. Nearly 100% survival of 
the second tumor inoculation was observed in the tested glioma models (Supplementary Fig. 6). Furthermore, 
specificity of the immune (memory) response was tested by inoculating another group of LT survivors with LLC 
cells (Supplementary Fig. 6C). All mice developed massive tumor growth, showing specific protection induced 
Figure 2. Pre-tumor lysate treatment results in similar survival improvement as compared to dendritic 
cell therapy in 2 glioma mouse models. Mice were treated with autologous lysate 14 and 7 days before 
tumor inoculation with 5 × 105 glioma cells. In the GL261 glioma model both (A) intraperitoneal and (B) 
subcutaneous injection of lysate (n = 16 and n = 10 respectively) were studied in comparison to PBS treatment 
(n = 9). (C) For the CT2A glioma model only subcutaneous lysate treatment was tested. Moreover, in the two 
bottom graphs (subcutaneous injection), dendritic cell therapy (n = 6) was performed and applied as a literature 
based control condition. For graphs (A) and (B) data of two independent experiments were pooled. Statistical 
significance was calculated by Log-rank test, *p < 0.05.
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Figure 3. Early after tumor inoculation, lysate treatment induced a T cell influx combined with diminished 
immune suppression in the brain. Brain immune contexture of pre-tumor treated mice was studied 7, 14, 21 and 
28 days after tumor inoculation. Graphs present kinetic analyses of different T cell population proportions in 
PBS treated (●) or lysate treated (∆) mice. Cell populations were defined by different stainings with (A) CD3+ 
lymphocytes as single cells, ZY-, CD45+, CD3+ gated to CD45+; (B) CD4+ T cells as single cells, ZY-, CD45+, 
CD3+, CD4+ gated to CD3+; (C) Tregs as single cells, ZY-, CD45+, CD3+, CD4+, FoxP3+ gated to CD4+; 
(D) IFNγ-producing CD4+ T cells as single cells, ZY-, CD45+, CD3+, CD4+, IFNγ+ gated to CD4+; (E) 
CD8+ T cells as single cells, ZY-, CD45+, CD3+,CD8+ gated to CD3+; (F) IFNγ-producing CD8+ T cells as 
single cells, ZY-, CD45+, CD3+,CD8+, IFNγ+ gated to CD8+. Statistical significance was calculated by two-
way ANOVA. Groups of mice consisted of 5 mice except for day 28, when 1 or 2 mice already died due to glioma 
growth in the lysate and PBS treated conditions respectively. Significant differences between two treatment 
conditions, PBS or lysate, are indicated by asterisks: *p < 0.05; **p < 0.01. The symbols $ and # below the graph 
title indicate significant changes over time within the PBS treated and lysate treated populations respectively. $ 
or #p < 0.05; ##p < 0.01.
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by GL261 or CT2A lysate treatment. All of these results demonstrate that pre-tumor lysate treatment gave rise to 
a tumor-specific memory response, protecting mice for long periods of time and from new tumor inoculation.
Combining temozolomide and lysate in a curative treatment model improves median survival 
of glioma-bearing mice. In a final set of experiments we wanted to test the lysate treatment in a thera-
peutic setting. Lysate treatment started early after tumor inoculation did not improve survival in comparison 
to untreated mice (data not shown). Therefore we continued with a more clinical relevant situation in which 
immunotherapy is performed after direct anti-tumoral therapy such as chemotherapy. For this, a curative treat-
ment strategy was implemented in the GL261 glioma model combining autologous lysate treatment and TMZ. 
Following tumor inoculation, mice were treated six times with 20 mg/kg bodyweight TMZ between day 5 and 16 
and subsequently with autologous lysate injections at day 21, 28 and 35. Similar to data published by Litterman 
et al.34, we observed a limited effect of the low TMZ concentration on the presence of T cells and myeloid cell 
populations in spleen, bone marrow and skin (data not shown). The combination of lysate and TMZ significantly 
improved the median survival with 80% as compared to mock treated mice and 20% in comparison to TMZ mon-
otherapy (Fig. 5). However, all mice finally died due to tumor growth. The absence of a ‘lysate alone’ condition is 
due to the fact that most PBS treated mice already show disease symptoms at day 21, which would be the first day 
to treat the mice in the ‘lysate alone’ group. Moreover, in a preliminary experiment, treatment with lysate alone at 
days 3, 7 and 11 after tumor inoculation showed no survival benefit (Supplementary Fig. 7). Collectively, immu-
notherapy using autologous lysate treatment has potential as an adjuvant therapy next to TMZ administration 
for glioma.
Subcutaneous, pre-tumor peptide vaccination results in comparable treatment efficacy as com-
pared to peptide loaded DC therapy in the GL261 glioma model. In regard of future perspective, 
we considered the use of peptide vaccination instead of autologous lysate vaccination. Glycoprotein 100 (gp100), 
tyrosinase-related protein 2 (TRP-2) and Ephrin A2 (EphA2) are 3 known onco-proteins for GL261 cell line35,36. 
Feasibility of peptide vaccination in the GL261 glioma model was addressed with the CD8 immunodominant 
epitopes of these three onco-proteins: gp10025–33 KVPRNQDWL, TRP-2180–188 SVYDFFVWL and EphA2682–689 
VVSKYKPM (all from lifeTein). Comparing subcutaneous injection of 10 µM peptide mixture (including an 
equal amount of each peptide) with DCs loaded with this peptide mixture, surprisingly resulted both in a compa-
rable survival benefit (Supplementary Fig. 8). From this it can be concluded that subcutaneous peptide injection, 
targeting known onco-proteins, can lead to survival benefit even without the addition of ex vivo grown DCs.
Discussion
Within this study, we have shown a positive effect of subcutaneous lysate injections on the survival of 
glioma-bearing mice. The induced immune response resulted in a brain T cell influx and diminished immune 
suppression combined with the generation of a tumor specific immunological memory. Moreover, an improved 
treatment effect of tumor lysate together with TMZ was observed. Based on previous studies within our group, we 
believe the immunogenicity of the lysate strongly impacts the induction of an immune response12,13.
To the best of our knowledge, this is the first preclinical study describing a treatment effect in a murine glioma 
model by injecting animals with just autologous whole tumor lysate. All publications regarding tumor lysate 
in the treatment of cancer reside mainly in two groups: the use in DC therapy or in combination with an adju-
vant15–23. The most striking observation in our study might be the fact that no ex vivo grown DCs or adjuvants 
were needed in this setting. Some authors did report the use of tumor lysate as a negative control condition15,17,22. 
We believe that lysate processed in our hands contains enough activation molecules to load and mature the host’s 
Figure 4. Long-lasting immunological memory induced by pre-tumor lysate treatment. Mice were treated with 
lysate >100 days prior to tumor inoculation with 5 × 105 glioma cells of the corresponding cell line. In both 
glioma models, GL261 and CT2A, lysate treated mice were compared to PBS treated control animals. Statistical 
significance was calculated by Log-rank test, **p < 0.01; ****p < 0.0001.
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DCs. Indeed, disrupting the cells via freeze/thawing leads to tumor cell necrosis, which has been shown to cause 
release of intracellular damage associated molecular patterns (DAMPs) e.g. mitochondrial DNA, uric acid and 
ATP37. Moreover, by using X-ray irradiation after the F/T steps, reactive oxygen species (ROS) are generated12,38. 
These ROS induce protein carbonylation, which increases the immunogenicity of the lysate12,38. As the activity 
of this lysate in DC therapy has already been demonstrated12, these observations support the hypothesis of lysate 
uptake and processing by skin-resident host DCs.
Originally, CD8+ T cells were considered the main component of the cellular immune response against cancer39. 
The role of CD4+ T cells was presumed to be limited to enhancing and sustaining the CD8+ T cell and B cell 
responses and regulation of the immune response acting as Treg cells39,40. More recently CD4+ T cells have been 
pointed out to have more direct roles in cancer immunity with the description of tumor-reactive, cytotoxic CD4+ 
T cells41–44. Within our study, the brain T cell influx at day 7 was described to originate from increased propor-
tions of CD4+ T cells. Moreover a clear decrease in Treg cells was observed. Although we have no direct proof, 
CD4+ T cells in our model could be involved both in sustaining CD8+ T cells as well as having cytotoxic effects. 
Using a kinetic brain immune-contexture study, focussing on T cells, we were able to detect changes over time 
with the biggest difference between treated and untreated animals as early as day 7. Although no significant dif-
ference in CD8+ T cells was detected between lysate treated and mock treated mice at any time point, an increase 
over time of (activated) CD8+ T cells could be observed. We consider this immune influx in the brain of PBS 
treated mice a tumor response. We hypothesize that the combination of the lower amount of Tregs and activation 
of CD8+ cells later on is able to attack the tumor in lysate treated mice. Importantly, we should mention a bias in 
our brain immune cell experiment. At day 28, the mock treated group already had two animal deaths whereas the 
lysate treated group only had one. This might result in slightly skewing of the data as these mice might have had 
the lowest numbers of (active) T cells in the brain with higher amounts of Tregs.
Based on the presented results, we cannot exclude the contribution of B cells to the immune response in the 
glioma mouse models. Due to the presence of the blood-brain barrier, antibody permeability is restricted and 
therefore the humoral response is largely ignored in brain tumor immunotherapy literature45. This contrasts with 
haematological malignancies, in which antibody responses are considered to have an important part in cancer 
treatment46.
In the current study we used two fully immunocompetent glioma mouse models: the standard GL261 model 
and the CT2A model. Both are syngeneic cell lines for C57BL/6 mice but originate from different cells, the former 
resembling more of an ependymoblastoma and the latter being more of an anaplastic astrocytoma (together with 
GBM forming the group of HGG)30. The murine GL261 glioma model is the standard model to test immunother-
apy in GBM29. CT2A cells resemble more the GBM phenotype due to an invasive nature, high mitotic index and 
cell density33. Although the CT2A cell line is stated to be low immunogenic13, we were able to show an implemen-
tation of an immunotherapeutic treatment modality using lysate treatment. Besides, this is to our knowledge the 
first report on brain immune cell infiltration in the CT2A model. Moreover, showing one-way cross-reactivity 
Figure 5. Combining Temozolomide and lysate in a curative treatment improves median survival of glioma-
bearing mice. To introduce a curative treatment strategy, lysate injection was combined with chemotherapy 
(temozolomide). First 20 mg/kg body weight of temozolomide was orally administered 6 times between day 5 
and 16, followed by subcutaneous lysate injection at days 21, 28 and 35. The combination of temozolomide and 
lysate was compared to PBS treated controls and temozolomide monotherapy. One representative experiment 
out of two; n = 5 in the PBS control group and n = 8 in both test conditions. Statistical significance was 
calculated by Log-rank test, *p < 0.05; ***p < 0.001.
www.nature.com/scientificreports/
8Scientific RepoRts | 7: 13902  | DOI:10.1038/s41598-017-12584-0
between CT2A and GL261 glioma cell lines can have important implications for paving the way to more univer-
sal immunotherapy treatment, as some researchers have suggested the use of multiple HLA-matching reference 
tumor cell lines to create an universal lysate18.
Within our therapeutic treatment experiment we used TMZ treatment, as an anti-tumor therapy, followed by 
immunotherapeutic autologous lysate injections. Clinical relevance for this treatment combination is provided 
by Shore et al. who describe the positive effect of combining both anti-tumor therapy and immunotherapy in 
prostate cancer47. Starting therapy with the anti-tumor effects of chemotherapy diminishes the tumor burden 
after which the tumor might recur. Lower tumor burden might also result in a tumor more susceptible to immu-
notherapy and thus immunotherapy can increase patient survival.
As already stated by our therapeutic treatment experiment as well as in literature, the strength of cancer 
immunotherapy lies in combining different treatment strategies48. In this context, tumor vaccination has already 
been successfully combined with immune checkpoint blockade, at preclinical level, and oncolytic virother-
apy at clinical level. Blocking the negative costimulatory receptor, programmed death 1 (PD-1), showed to be 
complementary with tumor vaccination in a mouse model of ovarian cancer as well as glioma49,50. Within these 
mice, increased levels of T cell activity, and especially CD8+ T cells, were observed while Treg suppression was 
attenuated. Moreover, immune checkpoint blockade therapies can mediate their effect through reactivation of 
neo-antigen specific T cells51. Likewise, clinical data suggest an anti-tumor effect due to reactivation of existing 
neo-epitope specific T cells52,53. On the other hand, two case reports by Schirrmacher et al. describe cancer treat-
ment by combining dendritic cell vaccination and the oncolytic Newcastle disease virus in a patient with prostate 
cancer and another one with breast cancer54,55. In both cases, patients continued a high quality of life after treat-
ment with a long lasting anti-tumor memory T cell response. Taken together, literature shows the importance 
of combining therapeutic strategies in the treatment of gliomas. Adding autologous lysate treatment might offer 
similar therapeutic options and next research in our model will evolve in that direction.
Finally, we are aware of a specific drawback of this study as no histopathological sections are investigated. 
Although flow cytometry indicates attraction of immune cells to the tumor, the possibility exists that they remain 
in the peri-tumoral environment without infiltrating the tumor itself. However, the study of tumor infiltrating 
cells results in more quantitative information and is generally accepted12,13,50,56. Our data are compatible with T 
cell activation as demonstrated here by IFN-γ production. A second drawback of our study is that we focus on 
murine survival which gives no complete insight in the mechanistical events underlying the survival advantage. 
However, we have clear indication of T cell activation and given the strong differences in murine survival depend-
ing on tumor lysate injection, both in pre-tumor implementation and in post-tumor implantation settings (when 
combined with TMZ), we consider these findings strong enough to find their way into clinical setting.
Taken together all results, autologous lysate treatment can be considered a possible immunotherapy strategy 
in the treatment of high grade gliomas.
Conclusion
The present study demonstrated that treatment using autologous whole tumor lysate can dose-dependently ini-
tiate an immune response that suppresses tumor growth of orthotopic gliomas. Therefore immunogenic lysate 
was produced by combining freeze/thawing of tumor cells with high dose gamma irradiation. The effectiveness 
of lysate treatment for gliomas offers a time and cost-effective approach in comparison to DC therapy, and thus it 
should be considered as a potential adjuvant treatment for glioma. However, further research is required to refine 
this treatment strategy and to improve therapeutic effects on gliomas. In respect to optimisation, nanoparticles 
form an attractive path combining lysate delivery and adjuvant properties.
Methods
Glioma cell lines and cell culture. GL261 glioma cells were kindly provided by Dr. Ilker Eyüpoglu from 
the University of Erlangen (Germany). CT2A cells were a generous gift from Prof. Holger Gerhardt from the 
Vesalius Research Center (VIB, Leuven, Belgium) with MTA obtained from Prof. Thomas N. Seyfried (Boston 
College, USA). Both C57BL/6 syngeneic tumor cell cultures were maintained at 37 °C under 5% CO2 in DMEM 
supplemented with 10% heat-inactivated fetal calf serum (FCS), 100 U/ml penicillin, 100 µg/ml streptomycin 
(pen/strep) and 2 mM L-glutamine (L-Glu) (all from Lonza, Verviers, Belgium).
Tumor lysate generation and FITC labeling. Starting with a concentration of 40 × 106 tumor cells per ml 
1% PBS/FCS, lysate was created by performing 6 freeze-thaw (F/T) cycles consisting of 3 minutes liquid nitrogen 
and 3 minutes 56 °C warm water bath. Afterwards the lysate was irradiated (IRR) with 60 Gy to increase immuno-
genicity12. Protein concentration was determined by Bradford protein assay (Bio-Rad, Temse, Belgium). Tumor 
cell avitality was checked with trypan blue dye exclusion.
In some experiments, lysate was labelled with fluorescein isothiocyanate (FITC) for the detection by micros-
copy and flow cytometry27. In short, 20 μl FITC (Sigma-Aldrich, Diegem, Belgium) dissolved in 5 mg/ml dimethyl 
sulfoxide (DMSO, WAK-chemie Medical, Germany) was added per mg protein in labeling buffer containing 
0.05 M boric acid and 0.2 M NaCl at pH 9.2 using a 10.000 molecular weight cut-off amicon ultra 15 centrifugal 
filter (Merck, Overijse, Belgium). After 2 h incubation at room temperature, unbound FITC was removed by gel 
filtration using an Econo-Pac® 10DG Column (Bio-Rad). Finally, the protein concentration was measured with a 
SmartSpec Plus Spectrophotometer (Bio-Rad) at 280 nm and 492 nm.
DC generation and culturing. Bone marrow derived DCs were obtained by isolation of femur and tibia 
from 8 to 10 weeks old female C57BL/6 J mice (Envigo, Horst, The Netherlands). Bone marrow was flushed 
using PBS followed by erythrocyte lysis. Finally, progenitor cells were counted (Micros 60, Horiba ABX, France) 
and cultured at 106 cells per ml DC-medium consisting of RPMI-1640 medium (Lonza) supplemented with 
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10% FCS, pen/strep, L-Glu, 50 µM β-mercaptoethanol (Sigma-Aldrich) and 20 ng/ml granulocyte-macrophage 
colony-stimulating factor (GM-CSF, Peprotech, US). At days 3 and 5 medium was refreshed and at days 6 and 7 
the cells were prepared for flow cytometry or microscopy. On day 7 iDCs can be collected to develop mature DCs 
using 100 µg glioma lysate per 106 cells in the above medium supplemented with 1 µg/ml Escherichia coli lipopol-
ysaccharide (LPS, Sigma-Aldrich). To check for maturation, maturation markers of DCs were stained (Table 1). 
Flow cytometry was performed using a LSR Fortessa Analyzer (BD Biosciences, Erembodegem, Belgium) and 
analysed using FlowJo software (Tree Star, Ashland, OR, US).
Analysis of lysate uptake by dendritic cells and presentation in MHC class I molecules. 
Immature DCs (iDCs) at day six of culture were seeded on coverslips for 24 hours and incubated with FITC-labelled 
lysate for 90 minutes. Afterwards, cells were washed extensively, followed by fixation and nucleus staining with DAPI 
(Sigma-Aldrich). To study uptake, surface FITC quenching with trypan blue was conducted using 10 min incubation 
in 0.1% (w/v) trypan blue solution57. In order to show antigen presentation by major histocompatibility complex class 
I (MHC-I) molecules, cells were washed after the 90 min incubation and matured during 24 hours. Cells were stained 
with PE-anti-MHC-I for 30 minutes before fixation and nucleus staining27. Finally, the coverslips were placed on micro-
scope slides and an Olympus BX41 Fluorescence Microscope (US) and LSM 510 meta confocal microscope (Zeiss, 
Germany) were used to examine the samples.
Orthotopic glioma mouse models. Female C57BL/6 J mice were treated prior to (pre-tumor treatment) 
or shortly after (therapeutic treatment) tumor inoculation. Unless stated otherwise, all experiments were per-
formed with 100 µg lysate of a 1 mg/ml concentration. For all in vivo experiments freshly prepared lysate was used 
and all injections were administered in a total volume of 100 µl. All animal experiments were approved by the 
bioethics committee of the KU Leuven and conducted according to international guidelines.
Pre-tumor treatment. Mice of 8 to 10 weeks old were intraperitoneally (i.p.) or subcutaneously (s.c.) (in the 
abdominal wall) injected 14 and 7 days before tumor inoculation. Treatment modalities consisted of PBS-treated 
(mock) controls and lysate treatment. At day 0, mice were intracranially injected with 5 × 105 glioma cells in a 
volume of 10 µl31. Briefly, mice were anaesthetized and fixed in a stereotactic frame. Tumor cells were injected 2 
mm posterior and lateral from the bregma at 3 mm depth. Afterwards, follow-up of the mice was performed two 
to five times a week by weight and scoring based on a neurological deficit scale adapted by Maes et al.31. Mice 
surviving longer than three times the median survival of mock treated animals were considered long-term (LT) 
survivors. Without any additional treatment, tumor inoculation was repeated in these animals at the contralat-
eral hemisphere. Naïve mice, older than 20 weeks, were used as age-matched control condition. In another set 
of experiments, tumor specificity was tested using a Lewis lung carcinoma (LLC) cell line, obtained from Prof. 
Patrizia Agostinis (KU Leuven, Belgium). Therefore LT surviving animals and age-matched controls were inocu-
lated subcutaneously with LLC cells or intracranially with glioma cells.
Therapeutic treatment. In these survival experiments lysate treatment was combined with temozolomide (TMZ) 
administration. Tumor inoculation was performed as described above and TMZ was prepared as described pre-
viously13. In brief, the content of Temodal® capsules (MSD, Hertfordshire, UK) together with an equal amount 
of L-Histidine was dissolved in a phosphate buffer and administered in a total volume of 200 µl by oral gavage 
(Schering-Plough, Belgium). Prior to treatment, mice were randomised over the different groups. Mice received 
20 mg/kg TMZ at days 5, 7, 9, 12, 14, 16 and subcutaneous lysate injections at day 21, 28 and 35.
Antigen Fluorochrome Company
Surface stainings – DC maturation
CD11c APC eBioscience
CD80 PE eBioscience
CD86 PE BD
CD40 PE BD
H2Kb (MHC-I) PE BD
IA/IE (MHC-II) PE BD
Surface stainings – Brain immune cells
CD45 AF700 eBioscience
CD3 FITC/PE eBioscience
CD4 PerCP Cy5.5/eF780 eBioscience
CD8 BV421 BD
NKp46 APC Biolegend
Intracellular stainings – Brain immune cells
Foxp3 PE eBioscience
IFN-γ PerCP Cy5.5 BD
Viability marker Zombie Yellow Biolegend
Table 1. Antibodies for flow cytometry.
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Brain immune cell isolation and characterisation. Mononuclear cells in the brain of pre-treated, 
CT2A-inoculated mice were isolated 7, 14, 21 or 28 days post tumor inoculation as previously described31. Briefly, 
isolated brains were digested in Collagenase D (Roche, Anderlecht, Belgium) and DNase (Invitrogen), and filtered 
prior to Percoll gradient centrifugation (Sigma). After recovering the mononuclear cell interphase, assessment of 
the immune cells was done by flow cytometry. Therefore surface staining for T cell markers was performed fol-
lowing zombie yellow viability staining (Table 1). Foxp3-PE staining kit (eBioscience, Vienna, Austria) was used 
according to the manufacturer’s protocol to detect intracellular Foxp3. For the intracellular IFN-γ staining, cells 
were stimulated for 3 hours in vitro with 100 ng/mL phorbol myristate acetate, 1 mg/mL ionomycin and 0.7 mg/mL 
monensin (all from Sigma-Aldrich). After viability and surface staining cells were permeabilized with a buffer 
containing 0.5% saponin and 0.5% bovine serum albumin prior to IFN-γ staining.
Statistical analysis. Two-way analysis of variance (ANOVA) testing was used for comparing multiple 
groups. Data are represented as median. Survival analyses were performed using the Log-rank (Mantel-Cox) test. 
All data were analysed using Graphpad Prism software 6 (Graphpad Software, San Diego, USA) and statistical 
significance was considered if p < 0.05.
Data Availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
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